Unknown

Dataset Information

Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma.


ABSTRACT: Glioblastoma is the most aggressive brain tumor with a median survival ranging from 6.2 to 16.7 months. The complex interactions between the tumor and the cells of tumor microenvironment leads to tumor evolution which ultimately results in treatment failure. Immunotherapy has shown great potential in the treatment of solid tumors but has been less effective in treating glioblastoma. Failure of immunotherapy in glioblastoma has been attributed to low T-cell infiltration in glioblastoma and dysfunction of the T-cells that are present in the glioblastoma microenvironment. Recent advances in single-cell sequencing have increased our understanding of the transcriptional changes in the tumor microenvironment pre and post-treatment. Another treatment modality targeting the tumor microenvironment

SUBMITTER: Jain S 

PROVIDER: S-EPMC8790087 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature